Carbonmark offers instant access to tens of millions of carbon credits, prioritizes user experience, and empowers institutional access to KlimaDAO's digital carbon infrastructure without additional fees.
SAN FRANCISCO, March 28, 2023 (Newswire.com)
-
Carbonmark launches as the go-to platform for acquiring, trading, and retiring digital carbon. It will serve as the gateway for users to access to the Digital Carbon Market (DCM) - the segment of the Voluntary Carbon Market which leverages the benefits of public blockchain technologies - giving access to tens of millions of carbon credits from hundreds of projects instantly.
Carbonmark prioritizes user experience with a seamless marketplace interface - it does not charge any platform fees for buyers or sellers and lists more carbon projects than any other carbon credit storefront thanks to the interoperable standards that KlimaDAO has helped to establish.
As a frictionless access point to the DCM on top of the Polygon blockchain, users can now source carbon credits with unprecedented transparency and speed. The platform does not require any authorization to access - as such, all carbon market stakeholders can plug into the marketplace.
With transparent pricing, and the ability to execute transactions using smart contract technologies, the marketplace stands to reduce transaction costs within the market and reduce lead times across the carbon market's entire value chain.
Speaking of the launch, Gabriel Kent, Head of Product at Carbonmark, said:
"The development of open, public, and neutral infrastructure that will unlock transparency and trust within the Voluntary Carbon Markets is of utmost importance if the market is to scale and fulfill its role in the fight against climate change.
Carbonmark is an essential infrastructure for sellers to create a carbon storefront and for buyers to search, purchase, or retire carbon credits instantly. We're excited to launch with the world's largest selection of digital carbon and with zero-commission trading. Carbonmark will revolutionize access to the Voluntary Carbon Market."
About Carbonmark
Carbonmark.com is the universal carbon marketplace, with the largest selection of digital carbon credits worldwide. Buy, sell, and retire digital carbon from any project instantly with zero-commission trading. Contact us.
Legionnaires' disease cases have increased nearly tenfold in recent decades, leading to thousands of hospitalizations and deaths. Outbreaks are linked to Legionella, a bacteria found in potable water systems in large facilities like hospitals, multi-family buildings, resorts, and office buildings. A recently published study shows that copper-silver ionization effectively controls Legionella in building water systems to prevent Legionnaires' disease.
Copper-Silver Ionization System A copper-silver ionization system installed in a building to prevent Legionella in the potable water supply.
LOMBARD, Ill., March 28, 2023 (Newswire.com)
-
A new study published in the American Water Works Association (AWWA) Water Science journal shows that copper-silver ionization effectively controls Legionella in building water systems. The study, conducted by Dr. Mark LeChevallier with technical and financial support from LiquiTech, examines more than 80 sources of research studies and related literature to analyze the efficacy of copper-silver ionization as a water treatment solution. Dr. LeChevallier concludes "that use of copper-silver ionization to control Legionella and other opportunistic pathogens is highly effective when the units are properly designed, maintained, and operated."
Legionnaires' disease cases have increased nearly tenfold in recent decades, leading to thousands of hospitalizations. Those who catch Legionnaires' disease experience a severe form of pneumonia caused by Legionella, a bacteria found in poorly maintained water systems.
Studies show that Legionella is responsible for about two-thirds of all disease outbreaks from drinking water and the cause of all documented deaths attributed to drinking water-associated infections.
Historically, outbreaks were linked to cooling tower systems. As our understanding of Legionella has advanced over recent decades, most outbreaks are now connected to potable water systems in large facilities, such as hospitals, long-term healthcare facilities, resorts, and office buildings. It's estimated that 54% of all potable building water systems have some level of Legionella present.
Plumbing codes and regulations have been developed to standardize the design, structure, and management of building water systems to prevent waterborne diseases. However, based on the studies cited in this article and elsewhere, there is a need for supplemental treatment of building water systems.
One such supplemental treatment is copper-silver ionization, a chemical-free disinfection solution for potable water systems. It releases copper and silver ions into the building's water system to destroy waterborne pathogens like Legionella.
Copper-silver ionization is not a new water treatment option. Silver ionization was used in the 1960s by NASA for the sanitation of water on spacecraft. In the 1980s, copper-silver ionization was used in swimming pools as an alternative to chlorine.
Later, in 1994, copper-silver ionization was the first reported effective treatment for controlling Legionella in a hospital. Today, copper-silver ionization is used to prevent waterborne pathogens in a variety of buildings with complex water systems.
Although copper-silver ionization is a low-cost and chemical-free option for water disinfection, the system must be designed properly and used in the appropriate applications to achieve optimal results. Crucial to its effectiveness is identifying and responding to abnormalities in water usage patterns and chemistry.
Dr. LeChevallier, a drinking water research scientist with a Ph.D. in Microbiology, examined literature and studies related to copper-silver ionization system design, maintenance, and operations, and the impact water chemistry has on its performance. In addition to authoring more than 300 research papers, Dr. LeChevallier is a member of the Drinking Water Subcommittee of the Science Advisory Board of the United States Environmental Protection Agency (US EPA), a past member of the Water Science Technology Board of the National Academies of Science, and the past Chair of the AWWA Water Science & Research Division.
In his recently published study, Dr. LeChevallier explained, "These water quality and operational characteristics must be properly addressed to assure that the highest disinfection efficacy is obtained through copper-silver ionization."
He reviewed research and related literature to investigate the mechanisms of copper and silver disinfection. Copper-silver ionization works by treating water through electrolysis. An electric current is applied to a copper and silver bar to produce and release positively charged ions. These copper and silver ions then find microorganisms in the water with a negative charge, like Legionella. The copper ions bond to the negative walls of the microorganisms, disrupting cell wall permeability and the absorption of life-sustaining nutrients. This disruption to the cell wall allows the silver ions to enter and destroy the core of the bacteria, thus making it impossible to survive.
Dr. LeChevallier cited studies showing that copper and silver can work as biocides independently or together. One study emphasized that combined treatment with copper and silver was associated with decreased incidence of Legionella and a faster reduction of bacteria than copper or silver alone.
In addition to copper-silver ionization being considered an effective supplemental method for water treatment by researchers, the US EPA has recognized both copper and silver as metallic antimicrobial agents. Studies show that copper-silver ionization is effective against many waterborne pathogens, including Legionella, Nontuberculous Mycobacterium, Pseudomonas, Stenotrophomonas, Acinetobacter, and fungi.
While the issue of copper-silver resistance was discussed in portions of the literature that Dr. LeChevallier reviewed, it's important to note that there was no evidence of it occurring with Legionella. Copper-silver resistance, where pathogens can continue to grow and thrive even in the presence of copper and silver, was only observed with E. coli and Salmonella.
During his investigation, Dr. LeChevallier found that the design, operation, and maintenance of copper-silver ionization systems are critical to their effective functionality. In his published paper, he explained that copper-silver ionization will act as a water disinfectant; however, the proper engineering and operation of the system are integral to its success.
Essential components of the copper-silver ionization system include the electrodes, flow cells, power supply, control panel, flow meter, and web interface. Each component must be operated and maintained for copper-silver ionization to be most effective.
"Buyers of [copper-silver ionization] systems should pay attention to the design and configuration of the electrodes - particularly as they wear. The construction of the flow cell and the adequacy of the power supply are important to deliver the necessary amperage to achieve the target copper and silver concentrations. Copper and silver doses should be flow paced and can be remotely monitored with a web-based interface," said Dr. LeChevallier.
Additionally, Dr. LeChevallier cautioned that water quality can impact copper-silver ionization as a water treatment. He explained that water chemistry, physiochemical, and environmental factors can influence the efficacy of copper-silver ionization if not considered and managed correctly.
Specific factors to consider include temperature, oxygen levels in the water, flow, pH levels, and levels of biofilm, sediment, and other chemicals that can impact the performance of copper-silver ionization. He stressed that these factors must be considered during planning, commissioning, and system operations for copper-silver ionization to be successful.
Dr. LeChevallier cited several case studies where copper-silver ionization was implemented in a building water system with positive outcomes. He explained that University of Pittsburgh researchers Dr. Stout and Dr. Yu found that copper-silver ionization is a viable proactive strategy for long-term Legionella control, specifically for healthcare facilities.
The studies collected data from 16 hospitals with copper-silver ionization systems over the course of five to 11 years. These studies found that 50% of the hospitals had not reported any indications of Legionella, and 43% had no indications for another five years.
In addition to the promising implementation of copper-silver ionization at hospitals, other case studies found benefits in multi-family buildings, hotels, and other specialized hospitals, including children's and veterans' hospitals.
Summarizing his findings, Dr. LeChevallier concluded, "This study has shown that [copper-silver ionization] can be effectively used for management of Legionella and other waterborne pathogens through the installation of a properly designed and maintained [copper-silver ionization] system and the details of the engineering and operation of the system are important to ensure the consistent delivery of copper and silver ions at their target levels."
About LiquiTech
For more than 30 years, LiquiTech has partnered with businesses worldwide to provide chemical-free, sustainable water treatment solutions. Their highly engineered approach brings together the right combination of products, services, and expertise to solve the most challenging water quality issues and help businesses get the most out of their water-bearing equipment. With more than 3,000 installations, LiquiTech is the worldwide leader in smart, clean solutions for water treatment. Learn more at liquitech.com.
Contact Information:
Kelsey Raftery
Director of Marketing [email protected]
847.738.0933
An innovator in virtual care, LTI is one of the fastest-growing companies in the Americas with a 1,256 percent growth rate between 2018 and 2021.
CHARLOTTE, N.C., March 28, 2023 (Newswire.com)
-
Let's Talk Interactive, Inc. (LTI), a leader in customizable virtual care solutions, is ranked number 50 in the Financial Times' fourth edition of The Americas' Fastest-Growing Companies, a ranking and special report on high-growth businesses in North, Central, and South America, based on companies with the strongest revenue growth between 2018 and 2021.
"It's an honor for Let's Talk Interactive, Inc. to be named among the Financial Times' fastest-growing companies," CEO and Founder Art Cooksey said. "This comes on the heels of being recognized by Inc magazine as well, reinforcing our standing as a company that has a high growth potential."
For this special report, the Financial Times examined over 7,000 public companies across 20 countries. The data was collected via desk research in official sources like publicly available earning presentations, investor relations, websites, and annual reports.
"We continue to innovate in the virtual care sector, one that has experienced challenges and consolidation recently," Cooksey said. LTI offers healthcare providers a HIPAA-compliant telehealth platform and medical device integrations that increase patient access to quality healthcare.
LTI's new enterprise telehealth platform, TrustVideo, is customizable with any workflow, can integrate with any EMR/EHR, and serves any medical use case. LTI's Medcart software pairs with medical hardware such as telemedicine carts, soft packs, and peripherals, which are all part of LTI's overall custom digital healthcare solutions that enable providers to evaluate patients remotely.
"We are continuing global growth with our partners, AWS, Ingram Micro, Liberty Wesco, and continue to focus on our mission to expand access to healthcare," Cooksey said. "We are experiencing tremendous growth and look forward to continuing to provide excellent telemedicine solutions to our customers."
As a leader in creating innovative digital healthcare solutions, the company's award-winning HIPAA-compliant software is enhanced with custom web and software development as well as provider network solutions that improve access to care at any time, from anywhere in the world.
About Let's Talk Interactive, Inc.
Let's Talk Interactive, Inc. is an innovator in telehealth that has developed the most complete and configurable HIPAA-compliant telemedicine platform in the world. Through proprietary telehealth software, medical hardware, and provider network solutions, LTI gives those in need instant access to care. Headquartered in Charlotte, NC, the company ranked No. 496 on the 2022 Inc. 5000 annual list of fastest-growing companies. LTI is committed to providing innovative solutions for patients and healthcare providers in the post-COVID-19 era. For more information about Let's Talk Interactive, visitwww.letstalkinteractive.com.
Contact Information:
Caitlin Wolf
PR and Communications Executive, LTI [email protected]
980-220-3777
VANCOUVER, Wash., March 28, 2023 (Newswire.com)
-
Today, in honor of National Choking Awareness Day, Sinceri Senior Living announced its partnership with LifeVac, a company that provides lifesaving choking devices.
"At Sinceri Senior Living, we partner with companies that create value for our residents, families, and shareholders," stated Kayla Wersal, Vice President of Programming for Sinceri Senior Living. "This is why we chose to partner with LifeVac, a non-invasive choking assistance device. As a leader in senior care and Alzheimer's, we realize how important it is to put the correct tools in the hands of our staff that will help keep our residents safe."
The LifeVac device offers a safe and effective way to save people from choking when other methods fail or cannot be performed. Wersal stated that Sinceri rolled out the partnership in February and encouraged each community to order the lifesaving device. LifeVac worked with Sinceri training its staff and making sure the orders were shipped to each of its locations.
"Since our partnership started, I am excited to announce that we have already saved two lives using LifeVac during choking incidents. We look forward to strengthening our partnership and continue saving lives."
Founded in 2010, LifeVac is the only portable, non-invasive airway clearance device registered and fully regulated by the FDA as a Class II suction device. LifeVac uses a one-way valve system, which means that when applied, air vents outside of the unit and not into the person who is choking. The rescue device uses a short burst of suction, with minimal air volume, to mimic a forceful cough. When the handle of the plunger is pushed down, air escapes through the vents; when the plunger handle is pulled back, negative pressure is generated, and it suctions out the lodged material. LifeVac's Airway Clearance Device is essential for seniors in wheelchairs, as standard choking protocols cannot be performed.
"It's so important for LifeVac to be available to take care of those that have taken care of us. The elderly are at a higher risk of choking and may not have an option in a choking emergency," stated Arthur Lih, the inventor of LifeVac. The two companies are looking forward to serving the seniors at Sinceri Senior Living and continuing to give them the excellent care they deserve.
About Sinceri Senior Living:
Sinceri Senior Living is a premier senior living management company that provides service to seniors in 21 states, serving approximately 3,800 seniors across the U.S. Sinceri Senior Living manages all levels of care, including independent living, assisted living, memory care, and skilled nursing communities. From the legacy of its first dedicated memory care community more than 35 years ago, Sinceri Senior Living has built a reputation for expertly managing senior living properties, including owned and managed facilities, with highly sought personalized care and exceptional, unique programming for residents and their families.
Enlyt Shine Aims to Guide Patients to Better Health through Journeys
ST. PETERSBURG, Fla., March 28, 2023 (Newswire.com)
-
The path to better health just got more efficient with Enlyt Shine now available for Payers & Providers. Over 150 Million in the US and 1.7 Billion people globally are affected by chronic conditions. Enlyt Shine's e-learning health platform offers definitive and comprehensive support from the world's most renowned experts following a critical diagnosis.
"I am thrilled to announce the launch of Enlyt Shine alongside my good friend Mike McGraw. Shine is the latest platform innovation delivering highly specialized care journeys that leverage custom content created by the world's leading physicians, gamification, and an accountability structure that focuses on one thing - Optimal healthcare outcomes!" said Scott Fielder, Enlyt Shine's Co-Founder. "With the addition of Enlyt Shine, Enlyt is the only member and patient access platform delivering an entire front to back suite of tools pre-connected to EHRs, Telehealth, Wayfinding, CRM, CMS, etc… and ready to transform the ways healthcare providers and payers develop long lasting and trusting relationships with their patients. I am so proud to serve alongside my teams in delivering Shine and our focus shining the light of hope and truth into users' health journeys."
Patients lack supportive wellness strategies from their healthcare providers. Enlyt Shine, in partnership with world-renown doctors and scientists, create category-specific masterclasses to support an array of treatment plans. Find out more about the problems we are solving with Enlyt Shine: https://enlythealth.com/shine-by-enlyt
About Enlyt Health
Enlyt Health helps organizations build Digital Front Doors faster by providing a Low Code Mobile Platform that breaks down silos, provides brand recognition, removes disjointed end user frustration and enhances patient experience all in one future innovation focused platform. Customers can deploy their Digital Front Door mobile application in as little as 90 days delivering exponentially higher ROI than ground up builds, the comfort of knowing their applications are built on an industry proven platform, and know their patients are getting industry leading patient engagement. Learn more at www.enlythealth.com.
Contact Information:
Ryan Blachly
COO [email protected]
888-223-1615
AUSTIN, Texas, March 28, 2023 (Newswire.com)
-
BrainCheck, creator of a digital cognitive assessment and care management platform, today announced the appointment of veteran healthcare executive Kim Rodriguez as its new Chief Executive Officer. The company has raised $21M to date and its products are used by 1,200 providers in over 400 primary care and neurology practices to manage the cognitive health of over 150,000 patients.
"I'm thrilled to welcome Kim to the BrainCheck team, as the company digitally transforms the early detection and treatment of cognitive diseases like Alzheimer's and other dementias," said Mike Smerklo, BrainCheck Board Member and General Partner at Next Coast Ventures. "She is a highly regarded leader with an excellent track record and extensive experience across healthcare, product development, and commercialization. Kim is uniquely positioned to lead the company as its growth accelerates."
Rodriguez's career has spanned 25 years in the healthcare and medical device industry, globally, across multiple therapeutic areas—including neurology, cardiology, and women's health. Most recently, as a Venture Partner at S3 Ventures, she supported the firm's healthcare investments. Earlier, she served as CEO & Co-Founder of Acessa Health—a venture-backed startup providing a minimally-invasive, uterine-sparing fibroid treatment for women. Under her leadership, the company raised $30M, launched a new product, obtained broad insurance coverage, and was acquired by Hologic for over $120M in upfront and expected follow-on payments.
Previously, Kim was CEO at Halt Medical and led the largest business unit, Vascular Intervention, at Spectranetics (acq. by Royal Philips for $2.2B). She has held senior leadership positions at Johnson & Johnson, Blockade Medical (acq. by Balt International), Concentric Medical (acq. by Stryker Neurovascular), Guidant Corporation (acq. by Abbott Vascular), and Microvena (acq. by ev3).
"I'm honored to serve the BrainCheck team, providers, and patients to advance a transformative solution at the intersection of healthcare and software," said Rodriguez. "Due to our country's aging population, Alzheimer's and other dementias are one of the largest blind spots in our healthcare system. With the power of BrainCheck's digital platform, we will greatly expand patient access to early detection, longitudinal tracking, and personalized care."
Cognitive impairment is extremely common and affects millions of people, but it is rarely diagnosed. BrainCheck provides an easy-to-use platform that enables primary care doctors to perform cognitive assessment and intervention at the point of care—in lieu of a referral to a specialist. Diagnosing and addressing problems sooner provides massive clinical benefit and relief to patients and families—all while saving healthcare costs and providing financial benefit to doctors and health systems.
About BrainCheck
BrainCheck is addressing a growing gap in care by providing a rapid, mobile cognitive assessment and decision support technology to physicians—empowering them to deliver high-quality, personalized, and reimbursable cognitive healthcare to patients at the point of care. Patients perform the assessment on any web-enabled device—either in the office or at home; their input is analyzed, and then objective, validated results are autogenerated for providers to inform diagnosis and track cognition over time. BrainCheck was founded in 2015 by neuroscientists and technologists Drs. Yael Katz and David Eagleman to help lessen the human and economic toll of cognitive impairment and dementia. BrainCheck is used by over 1,200 providers in over 400 primary care and neurology practices to manage the cognitive health of over 150,000 patients. By detecting cognitive changes early and tracking them over time, BrainCheck enables patients, caregivers, and clinicians to work together to implement personalized recommendations to preserve brain health and functional independence. To learn more, please visit braincheck.com.
All-new Yunuverse cloud community capabilities, now standard on the Yunu platform, make it possible for over 1,000 on-demand specialty-trained radiologists, technologists, and study staff to be invited and instantly participate in any of the 4,000 in-flight imaging clinical trials running on the system today. Cancer centers may now extend the reach of trial programs to satellite sites and imaging centers, improving patient access to sophisticated oncology trials.
Yunu is ensuring breakthrough therapies \n\u200bare accessible to everyone by delivering a new standard \u200bof clinical trial imaging workflow.
CARY, N.C., March 28, 2023 (Newswire.com)
-
Yunu, a clinical trials imaging assessment workflow and data management platform, has opened access to their new Yunuverse for collaboration among pharma sponsors, trial sites, clinical research organizations (CROs), and on-demand clinician groups to transform the way imaging-based trials are conducted. Yunu is a fast-growing VC-backed SaaS eClinical solution company that announced its Series A investment from First Analysis and exited from stealth in September of 2022. The company's technology has already been used in trials sponsored by over 400 pharma companies.
Yunu's success stems from a platform built with deep domain expertise in medical imaging and oncology research to deliver transparency and efficiency in every detail of the trial imaging workflow, from scheduling and billing to response criteria customization, performing imaging assessments, and audit readiness. Yunu's cloud-based system creates a much-needed collaboration environment across all trial stakeholders. Customers who already manage hundreds of trials within each site, including many of the nation's busiest NCI-designated Comprehensive Cancer Centers, can now effortlessly share imaging trial access, setup, staffing, and best practices with other sites and stakeholders within the application.
These new Yunu platform capabilities, called the Yunuverse, create an expansive network whereby Yunu stakeholders can invite new participants into their trials, including on-demand board-certified radiologists and other trial staffing resources, with no disruption or contracts, pre-set turn-around-times, and competitive 3rd party rates. Clinical research coordinators and administrative staff can choose local or offsite resources and make these selections on a trial-by-trial or individual study basis, with the freedom to adjust these preferences at any time.
As patient recruitment challenges and staffing shortages continue to plague clinical trials, the Yunuverse brings new avenues to extend trial access to new populations and augment trial teams, creating more diverse trials and accelerating the delivery of breakthrough therapies. Due to the difficulties imaging assessments present, trials have historically been limited to patient populations near the larger cancer centers that conduct them. As an alarming result, only 3% of US patients are enrolled in clinical trials where over 80% of Americans receive care. The Yunuverse is the first cloud collaboration tool to remove imaging barriers by decentralizing imaging assessments - patients and scanners can be in one location, with trial staff and physicians located anywhere.
"The Yunuverse addresses the vexing issues of patient access and staffing shortages in our nation's cancer centers and clinical trials programs. Current ways of working are insular, with each cancer center essentially on an island, being asked to run an increasing number of trials with a decreasing number of staff. Meanwhile, patients suffer from a lack of access because these trials are too difficult to run in community cancer centers and imaging centers," said Jeff Sorenson, Yunu Co-founder & CEO. He continued, "By facilitating collaboration across large and small sites, and by connecting CROs and pharma sponsors to sites in new ways, the Yunuverse is allowing institutions to rethink how they scale imaging operations in their clinical trials for the good of both patients and the research community."
The Yunuverse is being released in concert with two back-to-back industry events including the Outsourcing for Clinical Trials - Southeast conference in Raleigh, NC, on March 28th-29th and the Society for Clinical Research Sites - Global Oncology Site Solutions Summit in Austin, TX, on March 31st-April 1st.
ABILENE, Texas, March 28, 2023 (Newswire.com)
-
Chike Nutrition recently added Chai Latte Protein Iced Coffee to their lineup, a brand new flavor to savor and the first-of-its-kind protein chai product on the market. Chike Chai Latte Protein Iced Coffee is made with real coffee and black tea (not just chai-flavored like other options) and has a sweet blend of cinnamon, ginger, and clove for the perfect mix of spicy and sweet. Starting March 28, 2023, Chike Chai Latte Protein Iced Coffee will be available on Chike Nutrition's website and in participating grocery stores.
Chike Chai Latte Protein Iced Coffee gives you all of the taste and flavors of a traditional Chai Latte but with 20 grams of non-GMO whey protein, 150mg of caffeine, only 1 gram of sugar, and 120 calories per serving. Chike Chai Latte Protein Iced Coffee is perfect for an on-the-go snack or an afternoon pick-me-up.
This new addition follows the brand's commitment to creating healthy options that have a delicious flavor. A verified Chike Nutrition customer, Jasmine, left a 5-star review in 2020, stating, "At this point they could put out Chike water and we would rush to get it. If they ever put out a Chai Latte, it's over for us." The time has come, and Chike Chai Latte Protein Iced Coffee is now available for customers to enjoy.
Chike Chai Latte Protein Iced Coffee has a sweet and smooth flavor and an authentic Chai Latte taste with every sip. If someone has never had a Chai Latte before but enjoys drinks with a bit of spice and bite, such as Cinnamon or Pumpkin Spice, they will most likely love the Chike Chai Latte Protein Iced Coffee.
"This is an exciting launch for Chike Nutrition, not only because it's a new addition to our current flavor lineup but also because this is the first product like this on the market! Chike Nutrition's mission is to energize and empower your potential. We are excited to do that by offering Chike Chai Latte Protein Iced Coffee as an additional option. You have got to Chai this…you won't be disappointed!" said Mac Mascorro, Brand Manager of Chike Nutrition.
This delicious addition will help fill up one's cup and help power through their day. Chike Nutrition also offers healthy, low-sugar alternatives to coffeehouse favorites such as Mocha, Vanilla, and Caramel Protein Iced Coffee.
###
About Chike Nutrition
Chike Nutrition is based in Abilene, Texas, and proudly manufactures and produces all eight (and counting!) of their current flavors, ensuring the quality and consistency that Chike Nutrition demands in their products. You can find all flavors on Chike Nutrition's website and follow new recipes, flavor launches, and more on Instagram. Learn more about Chike in their overview video.
FREMONT, Calif., March 28, 2023 (Newswire.com)
-
Q'Apel Medical Inc. was granted the CE Mark under MDR for Walrus, their U.S. market-leading Balloon Guide Catheter (BGC) utilized in treating patients suffering an acute ischemic stroke. The Walrus BGC has been utilized by Neuro Interventional physicians since 2019 and has successfully treated over 20,000 patients in the United States.
The Walrus BGC is a unique development in the field of Mechanical Thrombectomy procedures. It provides physicians with not only the known benefits of BGC use clinically, but unique to Walrus, superior ease of use in preparation in these urgent procedures. Importantly, Walrus enables the physicians to navigate the catheter into a more distal location easily and safely compared to other systems, which is associated with improved patient outcomes from stroke.
"The anticipation of Walrus in our international markets has been enormous, and we look forward to the same performance and loyalty around Walrus we have been fortunate to experience in the United States," said King Nelson, Q'Apel Medical's CEO.
"We are thrilled to be entering the EU and other international markets with Walrus and providing more physicians in more countries the unparalleled performance of our flagship catheter. This CE Mark certification represents a significant growth milestone for Q'Apel Medical providing access to new markets," commented Jodie Fam, Chief Marketing Officer & GM International.
About Q'Apel Medical
Q'Apel Medical designs highly innovative technologies for neurovascular interventions and unmet clinical needs. Q'Apel's portfolio comprises three products, the Walrus Balloon Catheter System, the Wahoo Hybrid Access System and Armadillo Radial Access System. Before Walrus came along, balloon-based variable stiffness catheters brought all manner of technological constraints. Not anymore. By blending flow control, trackability, support, and access into one revolutionary solution, Walrus offers truly unmatched functionality. The Wahoo Hybrid Access System and Armadillo Radial Access System are dual-mode catheters and part of the SelectFlex™ Family of Neurovascular Catheters. These devices feature two distinct operational modes, allowing physicians to easily switch modes at any point during a clinical case and reducing the need for multiple catheters in challenging procedures.
Recently, JoBlo was invited to visit the set of Chris McKay’s Renfield, a action-comedy-horror reimagining of the classic master-servant relationship the title character has with the Prince of Darkness himself, Count Dracula (played by Nicolas Cage). While on set, a bunch of us got the chance to talk to Nicholas Hoult about playing the iconic character, working with Cage, and his own take on the classic Dracula mythos. Here’s a transcript of the group interview we got to participate in with Hoult!
So, it sounds like your character goes through quite a journey.
Yeah. Yeah, I guess. In this film, we pick up with Renfield. He’s kind of been working for Dracula for probably around 100 years, just under 100 years or so. So, the Renfield that we’ve seen in–you know, from Bram Stoker’s novels and from previous films, he’s kind of been living in his boss’s shadow in this very toxic relationship in a Devil Wears Prada way for a while, and then through the circumstance of this film kind of starts to, you know, realize that that’s not what he wanted in life, and he kind of got tricked and trapped into this relationship. And he starts to find his voice and capability to ultimately become a hero himself.
What’s your relationship to Dracula? Did you grow up watching the movies?
I–well, I didn’t really grow up watching them too much. I mean, I’ve been watching a lot of Hotel Transylvania with my little boy, so that’s probably more of the Dracula that I know.
I mean, I’d–you know, I’d seen the–in terms of horror movies, a lot like Young Frankenstein and whichever ones were, like, big through my childhood just coming out in ’90s. Sorry, I have a terrible memory.
Dracula Untold, the movie?
I didn’t see Dracula Untold. Sorry.
Bram Stoker’s Dracula?
I’ve see Bram Stoker’s Dracula, obviously. I’ve gone back and watched a lot of them for this. But, yeah, growing up, I wouldn’t say they were a big part of my life growing up.
But, yeah, I’ve gone back to watch and study them, and particularly like, Dwight Frye’s performance (in the 1931 Bela Lugosi version), I suppose, and trying to steal some stuff from him when possible, particularly that laugh and–
–Yes–.
He brought–when possible to fit it in, you know, and I do my best. I’ve just–and gone back and read the book again as well, just see if there was anything in there that I–but as I said, we’d kind of joining Renfield at a very different point in his journey at the start of this film.
So, that was one thing I wanted to ask you about, was Dwight Frye’s Renfield kind of stole the show in the original Dracula.
Right, right, right.
And I was curious, what did you borrow from him? I was going to ask about the laugh, but I’m not going to make you do it if you can’t.
The laugh I have tried to squeeze in a couple of times. Whether it stays in the edit and it keeps in the cut, we’ll see.
But I was curious what you borrowed from him and what do you do make it your own, because his performance was so iconically beautiful and sad and manic.
Yeah, yeah, yeah. I think this version of Renfield is not probably as manic in this story. He’s more worn down by his lifestyle and environment and always having protect Dracula and how he treats him.
But, yeah, the laugh, I mean, I had–you know, I’d just go back and listen audio of him. And also, I have a couple of times just taken bits of dialect from the book–or from that iteration of the film and tried to kind of weave that into this dialogue. But, again, it’s very different, because this was written–Ryan Ridley is writing in the more modern tone and voice. So, it’s a modern monster take.
(from left) Dracula (Nicolas Cage) and Renfield (Nicholas Hoult) in Renfield, directed by Chris McKay.
How has it been working with Nicholas Cage again? NOTE – the two starred together in Gore Verbinski’s The Weather Man (a Best Movie You Never Saw fave) when Hoult was a teenager.
It’s been so fun. Yeah, we did a film when I was 14. I played his son in a movie, and then I haven’t seen him since. But I’ve been such a–I mean, obviously, a fan of everything he’s done film-wise and acting-wise, but also just particularly recently with Pig and the–and I’ve watched the trailer for The Unbearable Weight of Massive Talent.
And the dedication he’s brought to this role and the ideas he’s got, the things he’s drawing from previous Dracula portrayals and what he’s bringing to it is really magical and powerful. And the dynamic between them I think is hopefully really working, because he’s just really passionate. He cares, and he loves acting, so he’s someone who’s dedicated, puts the time and work and wants to grow is very exciting.
Can we talk about Renfield’s diet?
I have been eating some bugs, yeah, mostly crickets. Did try some potato bugs. And dried ones that are flavored somewhat. Salt and vinegar I recommend, all these things that I never knew, which is kind of bizarre. I drew the line at, like, tarantulas and scorpions and stuff. And I was like, I don’t know if I want a–boiled and, like, shrink wrapped. And I was like, “That doesn’t seem so good.”
But the props team are amazing. They also build–create some, like, sweet versions. So, the cockroaches are actually made of caramel. They look exactly like a cockroach but it’s just gooey caramel. So, that was nice, rather than having to eat an actual cockroach. And, like, the worms were just gummy worms. And then the earth that they were in was just like ground up chocolate.
Like a dirty cake?
Yeah. Yeah, yeah. So, I was like this is–that was a good day. Yeah, so there has been some bug eating. And the concept behind the bug eating, and this obviously tracks back to the idea of that’s what gives–him consuming life forces was what gives him power. So, that’s kind of what gives him the edge when he’s caught in moments of peril. While having to protect Dracula, he eats a bug and gets that extra little bit of juice to be fighting.
You can read more from our Renfield set visit here, as well as a great 1:1 interview we got with Nicolas Cage about playing Dracula in the film. Renfield’s final trailer comes out tomorrow, and you can see the film in theaters as of April 14th!
